RESUMEN
Fatal familial insomnia (FFI) is a rare inherited prion disease characterized by sleep, autonomic, and motor disturbances. Neuro-ophthalmological abnormalities have been reported at the onset of disease, although not further characterized. We analyzed video recordings of eye movements of 6 patients with FFI from 3 unrelated kindreds, seen within 6 months from the onset of illness. Excessive saccadic intrusions were the most prominent findings. In patients with severe insomnia, striking saccadic intrusions are an early diagnostic clue for FFI. The fact that the thalamus is the first structure affected in FFI also suggests its role in the control of steady fixation. ANN NEUROL 2021;89:823-827.
Asunto(s)
Técnicas de Diagnóstico Oftalmológico , Insomnio Familiar Fatal/diagnóstico , Examen Neurológico , Adulto , Edad de Inicio , Electrooculografía , Movimientos Oculares , Femenino , Humanos , Insomnio Familiar Fatal/genética , Insomnio Familiar Fatal/fisiopatología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Proteínas Priónicas/genética , Estudios Retrospectivos , Movimientos Sacádicos , Tálamo/fisiopatología , Grabación en VideoRESUMEN
Fatal Familial Insomnia (FFI) is a hereditary prion disease caused by a mutation at codon 178 of the prion-protein gene leading to a D178N substitution in the protein determining severe and selective atrophy of mediodorsal and anteroventral thalamic nuclei. FFI is characterized by physiological sleep loss, which polygraphically appears to be a slow wave sleep loss, autonomic and motor hyperactivation with peculiar episodes of oneiric stupor. Alteration of autonomic functions is a great burden for FFI patients consisting in sympathetic overactivation, dysregulation of its physiological responses and disruption of circadian rhythms. The cardiovascular system is the most frequently and severely affected confirming the increased sympathetic drive with preserved parasympathetic responses. Sleep loss, autonomic and motor hyperactivation define Agrypnia Excitata (AE), which is not exclusive to FFI, but it has been canonically described also in Morvan Syndrome and Delirium Tremens. These three conditions present different pathophysiological mechanisms but share the same thalamo-limbic impairment of which AE is one of the possible clinical presentations. FFI, and consequently also AE, is a model for the investigation of the essential role of the thalamus in the organization of body homeostasis, integrating both sleep and autonomic function control.
Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Encéfalo/fisiopatología , Insomnio Familiar Fatal/fisiopatología , Enfermedades del Sistema Nervioso Autónomo/complicaciones , Homeostasis , Humanos , Insomnio Familiar Fatal/complicaciones , Siringomielia/complicaciones , Siringomielia/fisiopatología , Tálamo/fisiopatologíaRESUMEN
Fatal familial insomnia is a rare disease caused by a D178N mutation in combination with methionine (Met) at codon 129 in the mutated allele of PRNP (D178N-129M haplotype). FFI is manifested by sleep disturbances with insomnia, autonomic disorders and spontaneous and evoked myoclonus, among other symptoms. This study describes new neuropathological and biochemical observations in a series of eight patients with FFI. The mediodorsal and anterior nuclei of the thalamus have severe neuronal loss and marked astrocytic gliosis in every case, whereas the entorhinal cortex is variably affected. Spongiform degeneration only occurs in the entorhinal cortex. Synaptic and fine granular proteinase K digestion (PrPres) immunoreactivity is found in the entorhinal cortex but not in the thalamus. Interleukin 6, interleukin 10 receptor alpha subunit, colony stimulating factor 3 receptor and toll-like receptor 7 mRNA expression increases in the thalamus in FFI. PrPc levels are significantly decreased in the thalamus, entorhinal cortex and cerebellum in FFI. This is accompanied by a particular PrPc and PrPres band profile. Altered PrP solubility consistent with significantly reduced PrP levels in the cytoplasmic fraction and increased PrP levels in the insoluble fraction are identified in FFI cases. Amyloid-like deposits are only seen in the entorhinal cortex. The RT-QuIC assay reveals that all the FFI samples of the entorhinal cortex are positive, whereas the thalamus is positive only in three cases and the cerebellum in two cases. The present findings unveil particular neuropathological and neuroinflammatory profiles in FFI and novel characteristics of natural prion protein in FFI, altered PrPres and Scrapie PrP (abnormal and pathogenic PrP) patterns and region-dependent putative capacity of PrP seeding.
Asunto(s)
Insomnio Familiar Fatal/genética , Subunidad alfa del Receptor de Interleucina-10/genética , Interleucina-6/genética , Enfermedades por Prión/genética , Proteínas Priónicas/genética , Receptores del Factor Estimulante de Colonias/genética , Receptor Toll-Like 7/genética , Astrocitos/metabolismo , Astrocitos/patología , Corteza Entorrinal/metabolismo , Corteza Entorrinal/fisiopatología , Femenino , Gliosis/genética , Gliosis/fisiopatología , Humanos , Insomnio Familiar Fatal/fisiopatología , Masculino , Neuronas/metabolismo , Neuronas/patología , Enfermedades por Prión/fisiopatología , Tálamo/metabolismo , Tálamo/fisiopatologíaRESUMEN
Agrypnia (from the Greek: to chase sleep) excitata (AE) is a syndrome characterized by loss of sleep and permanent motor and autonomic hyperactivation (excitata). Disruption of the sleep-wake rhythm consists in the disappearance of spindle-delta activities, and the persistence of stage 1 non-rapid eye movement (NREM) sleep. Rapid eye movement (REM) sleep persists but fails to stabilize, appearing in short recurrent episodes, isolated, or mixed with stage 1 NREM sleep. Diurnal and nocturnal motor, autonomic and hormonal overactivity is the second hallmark of AE. Of particular interest is the finding that norepinephrine secretion is extremely elevated at all hours of the day and night whereas the nocturnal melatonin peak is lacking. Oneiric stupor is probably an exclusive sign of AE and consists in the recurrence of stereotyped gestures mimicking simple daily life activities. Agrypnia excitata aptly defines 3 different clinical conditions, fatal familial insomnia (FFI), an autosomal dominant prion disease, Morvan syndrome (MS), an autoimmune encephalitis, and delirium tremens (DT), the alcohol withdrawal syndrome. Agrypnia excitata is due to an intralimbic disconnection releasing the hypothalamus and brainstem reticular formation from cortico-limbic inhibitory control. This pathogenetic mechanism is visceral thalamus degeneration in FI, whereas it may depend on autoantibodies blocking voltage-gated potassium (VGK) channels within the limbic system in MS, and in the sudden changes in gabaergic synapses down-regulated by chronic alcohol abuse within the limbic system in DT.
Asunto(s)
Delirio por Abstinencia Alcohólica/complicaciones , Insomnio Familiar Fatal/complicaciones , Miocimia/complicaciones , Agitación Psicomotora/etiología , Trastornos del Inicio y del Mantenimiento del Sueño/etiología , Delirio por Abstinencia Alcohólica/fisiopatología , Animales , Atrofia , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Modelos Animales de Enfermedad , Humanos , Hipotálamo/fisiopatología , Insomnio Familiar Fatal/diagnóstico , Insomnio Familiar Fatal/fisiopatología , Sistema Límbico/fisiopatología , Melatonina/deficiencia , Ratones , Miocimia/inmunología , Miocimia/fisiopatología , Norepinefrina/metabolismo , Polisomnografía , Canales de Potasio con Entrada de Voltaje/inmunología , Agitación Psicomotora/fisiopatología , Formación Reticular/fisiopatología , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Fases del Sueño/fisiología , Trastorno de Movimiento Estereotipado/etiología , Taquicardia/etiología , Núcleos Talámicos/patología , Núcleos Talámicos/fisiopatologíaRESUMEN
OBJECTIVE: Studying the thalamic role in the cortical expression of the Sleep Slow Oscillation (SSO) in humans by comparing SSO features in a case of Fatal Familial Insomnia (FFI) and a group of controls. METHODS: We characterize SSOs in a 51-year-old male with FFI carrying the D178N mutation and the methionine/methionine homozygosity at the polymorphic 129 codon of the PRNP gene and in eight gender and age-matched healthy controls. Polysomnographic (21 EEG electrodes, two consecutive nights) and volumetric- (Diffusion tensor imaging Magnetic Resonance Imaging DTI MRI) evaluations were carried out for the patient in the middle course of the disease (five months after the onset of insomnia; disease duration: 10 months). We measured a set of features describing each SSO event: the wave shape, the event-origin location, the number and the location of all waves belonging to the event, and the grouping of spindle activity as a function of the SSO phase. RESULTS: We found that the FFI individual showed a marked reduction of SSO event rate and wave morphological alterations as well as a significant reduction in grouping spindle activity, especially in frontal areas. These alterations paralleled DTI changes in the thalamus and the cingulate cortex. CONCLUSIONS: This work gives a quantitative picture of spontaneous SSO activity during the NREM sleep of a FFI individual. The results suggest that a thalamic neurodegeneration specifically alters the cortical expression of the SSO. This characterization also provides indications about cortico-thalamic interplays in SSO activity in humans.
Asunto(s)
Insomnio Familiar Fatal/fisiopatología , Sueño/fisiología , Tálamo/fisiopatología , Encéfalo/patología , Encéfalo/fisiopatología , Estudios de Casos y Controles , Humanos , Insomnio Familiar Fatal/patología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Neuroimagen , Polisomnografía , Proteínas Priónicas , Priones/genética , Fases del Sueño/fisiologíaAsunto(s)
Insomnio Familiar Fatal/patología , Sueño/fisiología , Tálamo/fisiopatología , Mapeo Encefálico , Fluorodesoxiglucosa F18 , Historia del Siglo XX , Humanos , Insomnio Familiar Fatal/genética , Insomnio Familiar Fatal/historia , Insomnio Familiar Fatal/fisiopatología , Neurobiología , Tomografía de Emisión de Positrones/métodos , Tálamo/diagnóstico por imagenRESUMEN
Recent advances in neuropathology, genotyping, and physiochemical characterization of proteins have allowed for the classification and verification of MM2-thalamic Creutzfeldt-Jakob disease (CJD). CJD is a fatal neurodegenerative illness belonging to the transmissible spongiform encephalopathies, also known as prion diseases. Sporadic CJD is generally classified by the genotype at codon 129 of the prion protein gene and the distinct physiochemical features of the pathologic prion protein (PrP(sc)). The entity is characterized by methionine homozygosity at codon 129, type 2 PrP(sc), and, primarily, thalamic pathology (MM2-thalamic CJD). It shares clinical and pathologic similarities with the genetic prion disorder fatal familial insomnia; the MM2-thalamic phenotype has therefore been called sporadic fatal insomnia (SFI). SFI may also present like other neurodegenerative diseases, and common diagnostic findings that are seen in other forms of sporadic CJD may be absent.
Asunto(s)
Síndrome de Creutzfeldt-Jakob/genética , Síndrome de Creutzfeldt-Jakob/patología , Predisposición Genética a la Enfermedad/genética , Insomnio Familiar Fatal/genética , Insomnio Familiar Fatal/patología , Adulto , Anciano , Síndrome de Creutzfeldt-Jakob/fisiopatología , Diagnóstico Diferencial , Progresión de la Enfermedad , Femenino , Humanos , Insomnio Familiar Fatal/fisiopatología , Masculino , Persona de Mediana Edad , Mutación/genética , Proteínas PrPSc/genética , Valor Predictivo de las Pruebas , Cintigrafía/métodos , Enfermedades Talámicas/genética , Enfermedades Talámicas/patología , Enfermedades Talámicas/fisiopatología , Tálamo/diagnóstico por imagen , Tálamo/patología , Tálamo/fisiopatologíaRESUMEN
OBJECTIVE: Agrypnia Excitata (AE) is characterized by autonomic over-activity and cardiovascular fluctuations but direct evidence of sympathoexcitation is lacking. AE is a common feature of acquired (i.e. Morvan's syndrome--MS) and genetic (i.e. fatal familial insomnia--FFI) conditions where a dysfunction of the thalamo-limbic system has been suggested. The aim of this study is to report the first microneurographic recordings of sympathetic activity in acquired and genetic AE to investigate the pattern of sympathetic activation. METHODS: We describe two patients presenting acquired AE (MS) as demonstrated by elevated serum antibody levels to voltage-gated potassium channels and one patient with genetically confirmed FFI. Patients and fifteen sex and age-matched healthy controls underwent microneurography from peroneal nerve to assess muscle sympathetic nerve activity (MSNA) and heart rate (HR). RESULTS: Mean level of resting awake MSNA and HR was significantly increased in patients compared to controls. Patients presented a similar pattern of MSNA with a normal cardiac rhythmicity and a very high burst incidence expressed in approximately each cardiac beat. CONCLUSIONS: Acquired and genetic AE presented a resting awake sympathetic over-activity. SIGNIFICANCE: AE patients may develop high blood pressure and/or cardiovascular instability potentially increasing the morbidity/mortality of the underlying disorders.
Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Sistema Nervioso Autónomo/fisiopatología , Músculo Esquelético/inervación , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Sueño/fisiología , Sistema Nervioso Simpático/fisiopatología , Potenciales de Acción/fisiología , Anciano , Presión Sanguínea/fisiología , Estudios de Casos y Controles , Frecuencia Cardíaca/fisiología , Humanos , Hipotálamo/fisiopatología , Insomnio Familiar Fatal/fisiopatología , Masculino , Persona de Mediana Edad , Nervio Peroneo/fisiopatología , Siringomielia/fisiopatologíaRESUMEN
This review summarizes the pioneering steps culminating in the identification of a novel disease, fatal familial insomnia (FFI), a hereditary prion disease. Together with Morvan's chorea and delirium tremens, FFI is characterized by an inability to sleep associated with motor and autonomic overactivation. We named this pattern agrypnia excitata, a syndrome caused by a dysfunction in thalamolimbic circuits. This review highlights the strategic role of the limbic thalamus in the central autonomic network running from the limbic cortex to the lower brainstem and regulating sleep and wakefulness.
Asunto(s)
Nivel de Alerta/fisiología , Insomnio Familiar Fatal/fisiopatología , Sistema Límbico/fisiopatología , Red Nerviosa/fisiopatología , Sueño/fisiología , Delirio por Abstinencia Alcohólica/metabolismo , Delirio por Abstinencia Alcohólica/fisiopatología , Vías Autónomas/metabolismo , Vías Autónomas/patología , Vías Autónomas/fisiopatología , Humanos , Insomnio Familiar Fatal/genética , Insomnio Familiar Fatal/patología , Sistema Límbico/metabolismo , Sistema Límbico/patología , Miocimia/metabolismo , Miocimia/patología , Miocimia/fisiopatología , Red Nerviosa/metabolismo , Red Nerviosa/patología , Tálamo/patología , Tálamo/fisiopatologíaAsunto(s)
Insomnio Familiar Fatal/patología , Tálamo/patología , Encéfalo/patología , Resultado Fatal , Femenino , Alemania , Humanos , Procesamiento de Imagen Asistido por Computador , Insomnio Familiar Fatal/genética , Insomnio Familiar Fatal/fisiopatología , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Priones/genéticaRESUMEN
CONTEXT: Fatal familial insomnia (FFI) is a genetically transmitted neurodegenerative prion disease that incurs great suffering and has neither a treatment nor a cure. The clinical literature is devoid of management plans (other than palliative). Part 1 of this article reviews the sparse literature about FFI, including case descriptions. Part 2 of this paper describes the efforts of 1 patient (with the rapid-course Met-Met subtype) to contend with his devastating symptoms and improve the quality of his life. DESIGN: Interventions were based on the premise that some symptoms may be secondary to insomnia and not a direct result of the disease itself. Strategies (derived by trial and error) were devised to induce sleep and increase alertness. Interventions included vitamin supplementation, narcoleptics, anesthesia, stimulants, sensory deprivation, exercise, light entrainment, growth hormone, and electroconvulsive therapy. RESULTS: The patient exceeded the average survival time by nearly 1 year, and during this time (when most patients are totally incapacitated), he was able to write a book and to successfully drive hundreds of miles. CONCLUSION: Methods to induce sleep may extend and enhance life during the disease, although they do not prevent death. It is hoped that some of his methods might inspire further clinical studies.
Asunto(s)
Insomnio Familiar Fatal/patología , Insomnio Familiar Fatal/fisiopatología , Apoptosis , Encéfalo/metabolismo , Encéfalo/patología , Encéfalo/fisiopatología , Muerte , Humanos , Insomnio Familiar Fatal/psicología , Insomnio Familiar Fatal/terapia , Memoria , Priones/metabolismo , Autocuidado , Sueño , Privación de SueñoRESUMEN
CONTEXT: Fatal familial insomnia (FFI) is a genetically transmitted neurodegenerative prion disease that incurs great suffering and has neither a treatment nor cure. The clinical literature is devoid of management plans (other than palliative). Part 1 of this article reviews the sparse literature about FFI, including case descriptions. Part 2 describes the efforts of one patient (with the rapid-course Met-Met subtype) who contended with his devastating symptoms and improved the quality of his life. DESIGN: Interventions were based on the premise that some symptoms may be secondary to insomnia and not a direct result of the disease itself. Strategies (derived by trial and error) were devised to induce sleep and increase alertness. Interventions included vitamin supplementation, narcoleptics, anesthesia, stimulants, sensory deprivation, exercise, light entrainment, growth hormone, and electroconvulsive therapy (ECT). RESULTS: The patient exceeded the average survival time by nearly 1 year, and during this time (when most patients are totally incapacitated), he was able to write a book and to successfully drive hundreds of miles. CONCLUSION: Methods to induce sleep may extend and enhance life during the disease course, although they do not prevent death. It is hoped that some of his methods will inspire further clinical studies.
Asunto(s)
Insomnio Familiar Fatal/terapia , Autocuidado , Nivel de Alerta , Humanos , Insomnio Familiar Fatal/fisiopatología , Masculino , Persona de Mediana Edad , SueñoRESUMEN
Fatal familial insomnia (FFI) is a prion disease exhibiting the PRNP D178N/129M genotype. Features of this autosomal dominant illness are progressive insomnia, dysautonomia, myoclonus, cognitive decline and motor signs associated with thalamic nerve cell loss and gliosis. In contrast to the new variant of Creutzfeldt-Jakob disease (vCJD) the onset of FFI is in middle to late adulthood. We report two male patients who belong to a large German FFI kindred. They were examined clinically, and postmortem neuropathological examination was carried out in collaboration with the German reference centre for prion disease. Additionally, the prion protein gene (PRNP) was analysed. To identify further patients with disease onset under 30 years of age a comprehensive literature review was carried out. Two male patients presented with typical symptoms of FFI at the age of 23 and 24 years. In their kindred, the age of onset has never before been under 44 years of age. Our literature review identified five additional early onset cases who died at age 21 to 25 years. In all 22 reviewed FFI families the median manifestation age was 49.5 years. Although phenotypic variability of FFI is common, age of onset under 30 years has been considered to be a hallmark of vCJD with a mean manifestation at 27 years of age. Our findings underline that in addition to vCJD, FFI must be considered in cases of young-onset prion disease. This has considerable impact on clinical management and genetic counselling.